Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)

Overview of attention for article published in Frontiers in Cardiovascular Medicine, July 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 8 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 8,471 followers.

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE) https://t.co/vZC4ncfdoo

01 Aug 2022

Reply Repost Favourite

RT @FrontCVMedicine: New Research: Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular D…

31 Jul 2022

Reply Repost Favourite

New Research: Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE): Background Low-density lipoprotein… https://t.co/3mMj4Ld

18 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.